Follow The Filings

TXG 10X Genomics Inc.

Industrials, filed as 10X Genomics Inc (COMMON STOCK), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 2 managers in 2026 Q2, sold by 1

  • 3 Owners
  • Max 2.5%
  • $432M
  • 2 new 1 reduce

In 2026 Q2 Ben Jacobs and Stanley Druckenmiller opened positions in 10X Genomics, while Cathie Wood trimmed.

Who owns this now

Largest portfolio weights among holders, up to 2.5% (Cathie Wood, Ark Investment Management). Not free-float ownership.

  1. Cathie Wood Reduce 2.5%
  2. Ben Jacobs New 1.3%
  3. Stanley Druckenmiller New 0.30%

Who owns TXG

Sorted by value, long equity only, as of 2026 Q2.

History
Cathie Wood, Ark Investment Management 2.5% Reduce −14.6% 10,003,057 $384M History
Ben Jacobs, Anomaly Capital Management 1.3% New 1.3% 867,794 $33M History
Stanley Druckenmiller, Duquesne Family Office 0.30% New 0.30% 403,100 $15M History

3 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by TXG's executives, directors and 10% owners in the last 12 months, from their Form 4s

All TXG insider trades
  • None no insider bought on the open market
  • $2.4M sold by 1 insider outside a trading plan
  • $9.1M sold by 4 insiders under 10b5-1 plans
  1. Shehnaaz Suliman Director
    Planned sale
    $465K 5,723 shares at $81.19 19% of stake
    Traded Sep 22 Filed Sep 24
    ↗
  2. Serge Saxonov CEO
    Planned sale
    $2M 25,000 shares at $81.22 2.3% of stake
    Traded Sep 22 Filed Sep 24
    ↗
  3. Adam Taich CFO
    Planned sale
    $3M 46,388 shares at $64.57 13% of stake
    Traded Sep 9 Filed Sep 11
    ↗
  4. John R Stuelpnagel Director
    Sale
    $1.2M 20,000 shares at $61.75 5.7% of stake
    Traded Sep 3 Filed Sep 8
    ↗
  5. Serge Saxonov CEO
    Planned sale
    $668K 10,486 shares at $63.69 1% of stake
    Traded Aug 26 Filed Aug 28
    ↗
  6. Shehnaaz Suliman Director
    Planned sale
    $140K 2,207 shares at $63.65 7% of stake
    Traded Aug 24 Filed Aug 26
    ↗
  7. Sarah A. Teichmann Director
    Planned sale
    $432K 7,551 shares at $57.25 21% of stake
    Traded Aug 13–14 Filed Aug 17
    ↗
  8. John R Stuelpnagel Director
    Sale
    $1.2M 20,000 shares at $57.75 5.4% of stake
    Traded Aug 11 Filed Aug 13
    ↗
  9. Serge Saxonov CEO
    Planned sale
    $1M 30,000 shares at $34.44 2.6% of stake
    Traded Jun 22 Filed Jun 24
    ↗
  10. Shehnaaz Suliman Director
    Planned sale
    $187K 5,723 shares at $32.63 15% of stake
    Traded Jun 16 Filed Jun 18
    ↗
  11. Serge Saxonov CEO
    Planned sale
    $265K 10,718 shares at $24.71 0.9% of stake
    Traded May 26 Filed May 27
    ↗
  12. Serge Saxonov CEO
    Planned sale
    $123K 5,000 shares at $24.56 0.4% of stake
    Traded Apr 14 Filed Apr 16
    ↗
  13. Serge Saxonov CEO
    Planned sale
    $289K 15,000 shares at $19.26 1.3% of stake
    Traded Mar 23–24 Filed Mar 25
    ↗
  14. Serge Saxonov CEO
    Planned sale
    $367K 16,152 shares at $22.73 1.3% of stake
    Traded Mar 2 Filed Mar 4
    ↗
  15. Sarah A. Teichmann Director
    Planned sale
    $147K 7,579 shares at $19.41 22% of stake
    Traded Feb 25 Filed Feb 27
    ↗

Also filed in the last 12 months, not counted as buying or selling: 12 sales to cover taxes, 9 stock grants, 3 gifts, and 1 option exercise.

SEC filings

Recent issuer filings from EDGAR, 14 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.07 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $618.73M $610.78M $642.82M
Gross profit $409.31M $414.48M $443.88M
Gross margin * 66.2% 67.9% 69.1%
Net income -$255.1M -$182.63M -$43.54M
Net margin * -41.2% -29.9% -6.8%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $596.02M $584.39M $684.45M
Total non-current assets * $369.12M $334.25M $356.91M
Total assets $0.965B $0.919B $1.04B
Total current liabilities $127.16M $117.63M $153.45M
Total non-current liabilities * $96.94M $90.87M $91.58M
Total equity $741.04M $710.13M $796.33M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$15.2M $6.66M $136.05M
Cash from investing $133.49M -$32.63M -$13.44M
Cash from financing $13.67M $10.91M $6.8M
Net change in cash $131.93M -$15.22M $129.9M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.